Divalproex Sodium Extended-Release Tablets for schizophrenia
This study is completed in the United States. It is testing Divalproex Sodium Extended-Release Tablets for schizophrenia.
SchizophreniaBehavioralFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether Divalproex Sodium Extended-Release Tablets may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive Divalproex Sodium Extended-Release Tablets, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateMarch 2006
Recruitment status
Completed
Enrollment listed in the registry
60
Sponsor
Northwestern University
Sponsor type
University
Study type
Behavioral
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00306475
Official title
Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00306475. We help you review the study, but cannot decide medical eligibility.
Recruitment & locations
Completed
Nashville
FAQ
Questions about this study
Who is behind this study?
The study sponsor is Northwestern University, a university.
Does this study involve medication?
Yes. The study involves medication, including Divalproex Sodium Extended-Release Tablets and placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as completed.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
